Oxidative stress, alpha-tocopherol therapy, and atherosclerosis.

Andrea Harris, Sridevi Devaraj, Ishwarlal Jialal

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Atherosclerosis is the leading cause of morbidity and mortality in the United States. Evidence suggests that antioxidants, especially alpha-tocopherol (AT), have potential benefits with respect to cardiovascular disease. AT has been shown to decrease lipid peroxidation, to inhibit platelet adhesion, aggregation, and smooth muscle cell proliferation, to exert anti-inflammatory effects on monocytes, and to improve endothelial function. Low levels of AT are related to a higher incidence of cardiovascular disease and increased intakes appear to afford protection against cardiovascular disease. Although clinical trials with AT supplementation to date have been conflicting, the majority of evidence supports a benefit for AT supplementation in patients with pre-existing cardiovascular disease. Clearly, more clinical trials are required in individuals with increased oxidative stress before a definitive recommendation can be made with respect to AT supplementation in atherosclerosis.

Original languageEnglish (US)
Pages (from-to)373-380
Number of pages8
JournalCurrent Atherosclerosis Reports
Issue number5
StatePublished - Sep 2002
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Oxidative stress, alpha-tocopherol therapy, and atherosclerosis.'. Together they form a unique fingerprint.

Cite this